Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623671 · ClinicalTrials.gov registry record · Phase 2
Intravenous Infusion of CAP-1002 in Patients With COVID-19
A Phase 2 study, sponsored by Capricor.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT04623671 is a Phase 2 study that has completed, run by Capricor. The registered enrollment target is 55 participants.
The verdict
NCT04623671, a Phase 2 study, has completed, sponsored by Capricor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CAP-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-11-15 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623671
The ClinicalTrials.gov registry entry for NCT04623671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capricor, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04623671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04623671 about?
NCT04623671 is a clinical study titled "Intravenous Infusion of CAP-1002 in Patients With COVID-19". This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.
What is the current status of trial NCT04623671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-11-15. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT04623671?
The interventions under investigation include: Placebo (BIOLOGICAL), CAP-1002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04623671?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.